Your shopping cart is currently empty

KI-TOX-A3 is a selective protein-protein interaction (PPI) inhibitor targeting the TOX protein, with an IC50 value of 0.51 μM for the TOX-KAT7 interaction. It promotes proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses CD8+ T cell exhaustion, and inhibits proliferation of T-cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 holds potential for research in hematological malignancies, including T-ALL.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | KI-TOX-A3 is a selective protein-protein interaction (PPI) inhibitor targeting the TOX protein, with an IC50 value of 0.51 μM for the TOX-KAT7 interaction. It promotes proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses CD8+ T cell exhaustion, and inhibits proliferation of T-cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 holds potential for research in hematological malignancies, including T-ALL. |
| Molecular Weight | 319.31 |
| Formula | C18H13N3O3 |
| Cas No. | 1351116-34-1 |
| Smiles | N#CC1=C(N=C2C=3C=CC(O)=CC3CC2=C1C=4OC(=CC4)CO)N |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.